Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | TYR | P14679 | 1/20 | 0.65 |
| ▸ | CA7 | P43166 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.65 |
| ▸ | JUN | P05412 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | TTR | P02766 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10398774 | 1.00 | KDM4E (0.68) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL4683429 | 1.00 | KDM4E (0.68) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL9250169 | 0.87 | KDM4E (0.55) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL9247583 | 0.87 | KDM4E (0.55) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL71224 | 0.86 | CA12 (0.84) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL5057418 | 0.86 | CA12 (0.84) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL21001858 | 0.84 | JUN (0.67) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL7747441 | 0.82 | KDM4E (0.61) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL7747445 | 0.82 | KDM4E (0.61) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL9104771 | 0.80 | CA12 (0.54) | KDM4EMAPTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101944-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20240217932-A1 | PYRIDIUM ESTERS | THE PROCTER AND GAMBLE COMPANY | 2024-07-04 | — | — | US | disclosed |
| US-11760743-B2 | Acyloxy substituted phenyl dithiane derivatives | Renovel Innovations, Inc. | 2023-09-19 | — | — | US | disclosed |
| US-20230285372-A1 | Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives | MEDCURIUS INC. (CN) | 2023-09-14 | — | — | US | disclosed |
| US-20230285372-A1 | Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives | MEDCURIUS INC. (CN) | 2023-09-14 | — | — | US | disclosed |
| WO-2021259143-A1 | PHARMACEUTICAL USE OF (E)-3-ARYLHETEROCYCLYL PROP-2-ENOIC ACID DERIVATIVES | 上海长车生物科技有限公司 | 2021-12-30 | — | — | WO | disclosed |
| US-20190002454-A1 | NRF2 Regulators | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-01-03 | — | — | US | disclosed |
| US-20190002454-A1 | NRF2 Regulators | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-01-03 | — | — | US | disclosed |
| US-10144731-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-04 | — | — | US | disclosed |
| CN-105829305-B | NRF2 regulator | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-11-30 | — | — | CN | disclosed |
| US-5382578-A | Anticonvulsants or antiischemic agents | G. D. SEARLE & CO. (US) | 1995-01-17 | — | — | US | disclosed |
| US-5380721-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0610303-A1 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS AS ANALGESIC AGENTS | G.D. SEARLE & CO. (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0597540-A1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1994-05-18 | — | — | EP | disclosed |
| EP-0425211-B1 | Substituted 5-((tetrazolyl)alkenyl)-imidazoles | SMITHKLINE BEECHAM CORP (US) | 1994-03-30 | — | — | EP | disclosed |
| US-5288719-A | 2-,3-,8-and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating osteoporosis | G. D. SEARLE & CO. (US) | 1994-02-22 | — | — | US | disclosed |
| US-5212169-A | Analgesics | G. D. SEARLE & CO. (US) | 1993-05-18 | — | — | US | disclosed |
| WO-1993009105-A1 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS AS ANALGESIC AGENTS | G.D. SEARLE & CO. (US) | 1993-05-13 | — | — | WO | disclosed |
| EP-0539977-A1 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ANALGESIC AGENTS AND PROSTAGLANDIN ANTAGONISTS | G.D. Searle & Co. (US) | 1993-05-05 | — | — | EP | disclosed |
| EP-0425211-A1 | Substituted 5-((tetrazolyl)alkenyl)-imidazoles | SMITHKLINE BEECHAM CORPORATION (US) | 1991-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760743-B2 | Acyloxy substituted phenyl dithiane derivatives | AADAC, TBXA2R, DECR2 | KDM4E 1877/4885MAPT 3050/4885CA12 964/4885 |
| US-20190002454-A1 | NRF2 Regulators | NFE2L2, KEAP1, NQO1 | KDM4E 1805/4885MAPT 1861/4885CA12 4870/4885 |
| US-20240217932-A1 | PYRIDIUM ESTERS | C5, CBR3, CHRM1 | KDM4E 1739/4885MAPT 4762/4885CA12 3752/4885 |
| US-20230285372-A1 | Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives | NFE2L2, NFE2, TXNRD2 | KDM4E 3813/4885MAPT 3234/4885CA12 4585/4885 |
| US-10144731-B2 | Nrf2 regulators | NFE2L2, KEAP1, NQO1 | KDM4E 1805/4885MAPT 1861/4885CA12 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.